Opening Asia for Russia

Uzbekistan launches production of Russian vaccine Sputnik V

14.09.2021 57 просмотров

Serial production of the Russian Sputnik V vaccine has begun in Uzbekistan.


Serial production of the Russian coronavirus vaccine Sputnik V has begun in Uzbekistan at Jurabek Laboratories, which expects to start deliveries to the Uzbek market in October. This was reported on Tuesday by Gazeta.uz with reference to the head of the marketing and sales department of Jurabek LaboratoriesAziz Saipov.

“Bottling has already begun. We send each series to Russia for control. The analysis takes about three weeks. In the Russian Federation and in the laboratory of the state center (Uzbekistan - TASS note), control is going on in parallel. As soon as the answers come out, we will be able to ship [the vaccine to the Ministry of Health of Uzbekistan],” the publication quotes Aziza Saipov. The representative of the company specified that the drug will enter the domestic market in October.

According to Aziz Saipov, samples of the Sputnik V vaccine, mass-produced" in Uzbekistan, were sent to the developer for quality control the drug - to the Russian National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya, as well as to the State Center for Expertise and Standardization of Medicines, Medical Devices and Medical Equipment under the Agency for the Development of the Pharmaceutical Industry of Uzbekistan.

The first batch of the Russian vaccine Sputnik V was produced at the Jurabek laboratories in the city of Almalyk, Tashkent region of Uzbekistan, the Russian Direct Investment Fund (RDIF) said at the end of July. The plant's capacity is 2 million doses of Sputnik V per month.

Mass vaccination of the population in Uzbekistan began in April. As part of the vaccination campaign, the Russian Sputnik V vaccine, a drug manufactured in India under license from the British-Swedish company AstraZeneca, a vaccine from the Chinese company Anhui Zhifei Longcom Biopharmaceutical, and a drug from the American company Moderna are used. According to the latest data, in a republic with a population of about 35 million people, more than 3.12 million people have been fully vaccinated, and almost 10 million people have received the first component of one of the vaccines.

Новости партнёров